DK141682B - Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. - Google Patents

Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. Download PDF

Info

Publication number
DK141682B
DK141682B DK53170AA DK53170A DK141682B DK 141682 B DK141682 B DK 141682B DK 53170A A DK53170A A DK 53170AA DK 53170 A DK53170 A DK 53170A DK 141682 B DK141682 B DK 141682B
Authority
DK
Denmark
Prior art keywords
membrane
gelling
ultrafiltration
macromolecules
solute
Prior art date
Application number
DK53170AA
Other languages
Danish (da)
English (en)
Other versions
DK141682C (Direct
Inventor
Heinrich Strathmann
Richard William Baker
Original Assignee
Amicon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amicon Corp filed Critical Amicon Corp
Publication of DK141682B publication Critical patent/DK141682B/da
Application granted granted Critical
Publication of DK141682C publication Critical patent/DK141682C/da

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/18—Apparatus therefor

Landscapes

  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
DK53170AA 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler. DK141682B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79692869A 1969-02-05 1969-02-05
US79692869 1969-02-05

Publications (2)

Publication Number Publication Date
DK141682B true DK141682B (da) 1980-05-27
DK141682C DK141682C (Direct) 1980-10-20

Family

ID=25169415

Family Applications (1)

Application Number Title Priority Date Filing Date
DK53170AA DK141682B (da) 1969-02-05 1970-02-03 Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler.

Country Status (10)

Country Link
US (1) US3541005A (Direct)
JP (1) JPS4931431B1 (Direct)
BE (1) BE745442A (Direct)
DE (1) DE2005260A1 (Direct)
DK (1) DK141682B (Direct)
FR (1) FR2033961A5 (Direct)
GB (1) GB1307331A (Direct)
NL (1) NL7001662A (Direct)
SE (1) SE350702B (Direct)
ZA (1) ZA70548B (Direct)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2254860C3 (de) * 1971-11-26 1984-03-29 Heinrich Frings Gmbh & Co Kg, 5300 Bonn Ultrafiltrationsverfahren für Flüssigkeiten, die Mikroorganismen, Makromoleküle oder andere kleine Feststoffteilchen enthalten
JPS568476U (Direct) * 1979-06-30 1981-01-24
JPS56110625A (en) * 1980-02-05 1981-09-01 Takeda Chem Ind Ltd Separating method of blood plasma and apparatus for the same
US4735726A (en) * 1981-07-22 1988-04-05 E. I. Du Pont De Nemours And Company Plasmapheresis by reciprocatory pulsatile filtration
US4769150A (en) * 1982-02-16 1988-09-06 E. I. Du Pont De Nemours And Company Method and apparatus for plasmapheresis by reciprocatory pulsatile filtration
US4636312A (en) * 1982-02-16 1987-01-13 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved end plate
US4640776A (en) * 1982-02-16 1987-02-03 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having pressure balancing and sealing means
US4639317A (en) * 1982-02-16 1987-01-27 E. I. Du Pont De Nemours And Company Plasmapheresis filtration module having improved sealing means
DE3525668A1 (de) * 1984-10-31 1986-05-07 Kernforschungsanlage Jülich GmbH, 5170 Jülich Verfahren zur bestimmung des gehaltes an in einem loesungsmittel geloesten stoffen
US4693886A (en) * 1985-04-22 1987-09-15 Alza Corporation Osmotic device with inert core
US5340590A (en) * 1987-06-25 1994-08-23 Alza Corporation Delivery system with bilayer osmotic engine
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5391381A (en) * 1987-06-25 1995-02-21 Alza Corporation Dispenser capable of delivering plurality of drug units
US4969884A (en) * 1988-12-28 1990-11-13 Alza Corporation Osmotically driven syringe
US5273752A (en) * 1989-07-18 1993-12-28 Alza Corporation Controlled release dispenser comprising beneficial agent
US5126142A (en) * 1989-07-18 1992-06-30 Alza Corporation Dispenser comprising ionophore
US5035897A (en) * 1989-09-05 1991-07-30 Alza Corporation Dosage form for delivering soluble or insoluble drugs
US4986918A (en) * 1989-11-08 1991-01-22 Romicon Inc. Membrane separation system and method of operation
US5030216A (en) * 1989-12-15 1991-07-09 Alza Corporation Osmotically driven syringe
US5474785A (en) * 1990-01-24 1995-12-12 Alza Corporation Delivery system comprising means for controlling internal pressure
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
US5240713A (en) * 1991-09-27 1993-08-31 Alza Corporation Dual rate agent delivery device
US5200194A (en) * 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
US5532003A (en) * 1994-01-18 1996-07-02 Alza Corporation Pentoxifylline therapy
US5540665A (en) * 1994-01-31 1996-07-30 Alza Corporation Gas driven dispensing device and gas generating engine therefor
US20040191314A1 (en) * 1994-04-28 2004-09-30 Frank Jao Antiepileptic dosage form and process for protecting antiepileptic drug
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
EP0749038A1 (en) 1995-06-16 1996-12-18 Minnesota Mining And Manufacturing Company Light-sensitive photographic materials comprising tabular silver halide grains and azodicarbonamide derivatives
US6110499A (en) * 1997-07-24 2000-08-29 Alza Corporation Phenytoin therapy
US6514530B2 (en) 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DK1035834T3 (da) 1997-12-05 2002-07-08 Alza Corp Osmotisk doseringsform omfattende en første og anden coating
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ505193A (en) 1997-12-22 2003-03-28 Euro Celtique S Opioid agonist/antagonist combinations
US8524277B2 (en) * 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US6245357B1 (en) 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6551613B1 (en) * 1998-09-08 2003-04-22 Alza Corporation Dosage form comprising therapeutic formulation
US6174547B1 (en) 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
GB9822854D0 (en) 1998-10-21 1998-12-16 Reckitt & Colmann Prod Ltd Improvements in or relating to organic compositions
CN1325301A (zh) 1998-11-02 2001-12-05 阿尔扎有限公司 活性物质的控制释放
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6319510B1 (en) 1999-04-20 2001-11-20 Alayne Yates Gum pad for delivery of medication to mucosal tissues
AU2084801A (en) * 1999-12-09 2001-06-18 Alza Corporation Antiviral medication
CN100518827C (zh) 2000-10-30 2009-07-29 欧罗赛铁克股份有限公司 控释氢可酮制剂
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
ES2361148T3 (es) 2001-05-11 2011-06-14 Endo Pharmaceuticals Inc. Forma de dosificación de opioides de liberación controlada resistente al abuso.
WO2003007802A2 (en) 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
EP1492509A1 (en) * 2001-12-18 2005-01-05 ALZA Corporation Dosage form providing time-varying patterns of drug delivery
NZ533060A (en) * 2001-12-19 2006-03-31 Alza Corp Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
IL162294A0 (en) * 2001-12-19 2005-11-20 Alza Corp Formulation & dosage form for the controlled delivery of therapeutic agents
PT1492505E (pt) 2002-04-05 2015-10-06 Euro Celtique Sa Preparação farmacêutica contendo oxicodona e naloxona
EP1499291B1 (en) * 2002-04-29 2009-01-07 ALZA Corporation Methods and dosage forms for controlled delivery of oxycodone
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
IL165361A0 (en) * 2002-05-31 2006-01-15 Alza Corp Dosage forms and compositions for osmotic deliveryof variable dosages of oxycodone
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
NZ537543A (en) * 2002-07-29 2007-08-31 Alza Corp Formulations and high dose osmotic dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
DE60313359T2 (de) * 2002-12-17 2008-01-03 Abbott Gmbh & Co. Kg Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US7259186B2 (en) * 2002-12-17 2007-08-21 Abbott Laboratories Salts of fenofibric acid and pharmaceutical formulations thereof
WO2004064772A2 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
EP1592410B1 (en) * 2003-02-11 2008-07-23 Alza Corporation Methods and dosage forms with modified layer geometry
EP1905435A3 (en) 2003-03-11 2008-05-14 Euro-Celtique S.A. Titration dosing regimen for controlled release tramadol
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
CA2529852A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
CA2534920A1 (en) * 2003-08-06 2005-02-24 Alza Corporation Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2005020957A2 (en) * 2003-08-22 2005-03-10 Alza Corporation Stepwise delivery of topiramate over prolonged period of time
US20050069587A1 (en) * 2003-09-02 2005-03-31 Modi Nishit Bachulal Novel drug compositions and dosage forms of topiramate
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
MXPA06003452A (es) * 2003-09-26 2006-08-31 Johnson & Johnson Formulaciones de liberacion controlada que exhiben una velocidad de liberacion ascendente.
NZ546182A (en) * 2003-09-26 2009-08-28 Alza Corp Controlled release formulations of opioid and nonopioid analgesics such as hydrocodone and acetaminophen
EP2184058B1 (en) 2003-09-26 2012-02-08 ALZA Corporation Drug coating providing high drug loading and methods for providing the same
JP2007511519A (ja) * 2003-11-14 2007-05-10 アルザ・コーポレーシヨン 液状投薬形態物におけるトピラメートの制御放出
US20050158365A1 (en) * 2003-12-22 2005-07-21 David Watson Drug delivery device with mechanical locking mechanism
US20050136095A1 (en) * 2003-12-22 2005-06-23 Brian Levy Drug delivery device with suture ring
US20050169992A1 (en) * 2003-12-23 2005-08-04 Frank Jao Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
CA2550699A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
EP1701706A2 (en) * 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms
TWI365880B (en) 2004-03-30 2012-06-11 Euro Celtique Sa Process for preparing oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone and oxycodone hydrochloride composition,pharmaceutical dosage form,sustained release oeal dosage form and pharmaceutically acceptable package having less than 25 pp
US20060009425A1 (en) * 2004-05-28 2006-01-12 Leticia Delgado-Herrera Oral formulations of paricalcitol
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
WO2006007351A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Squeeze controlled oral dosage form
CA2571554A1 (en) * 2004-06-28 2006-01-19 Alza Corporation A drug/polymer complex, preferably ciprofloxacin/hpmc, its method of manufacturing using lyophilization and its use in an osmotic device
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
US8541026B2 (en) * 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2006039459A1 (en) * 2004-09-30 2006-04-13 Bausch & Lomb Incorporated Capsule for encasing tablets for surgical insertion into the human body
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
ES2704482T3 (es) 2004-11-24 2019-03-18 Meda Pharmaceuticals Inc Composiciones que comprenden azelastina y sus métodos de uso
AR053986A1 (es) 2004-12-03 2007-05-30 Osmotica Pharmaceutical Argent Dispositivo osmotico que contiene amantadina y una sal osmotica
US20060134162A1 (en) * 2004-12-16 2006-06-22 Larson Christopher W Methods for fabricating a drug delivery device
CA2596029A1 (en) * 2005-01-27 2006-08-03 David E. Edgren Oral osmotic dosage form having a high flux membrane
EP3228308A1 (en) * 2005-01-28 2017-10-11 Euro-Celtique S.A. Alcohol resistant dosage forms
US8318210B2 (en) * 2005-02-28 2012-11-27 Neos Therapeutics, Lp Compositions and methods of making sustained release liquid formulations
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US20080152714A1 (en) * 2005-04-08 2008-06-26 Yi Gao Pharmaceutical Formulations
US20060233882A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Osmotic dosage form
KR20080005429A (ko) * 2005-04-19 2008-01-11 알자 코포레이션 트라마돌 및 가바펜틴을 포함하는 물질의 배합물
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP2119442A4 (en) 2006-12-28 2010-12-15 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH TACROLIMUS MAINTAINED RELEASE
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
US8895061B2 (en) * 2007-03-02 2014-11-25 Meda Pharmaceuticals Inc. Compositions comprising carisoprodol and methods of use thereof
EP2164631A4 (en) * 2007-05-30 2013-08-21 Neos Therapeutics Lp MODIFICATION OF DRUG RELIEF IN SUSPENSIONS OF IONIC RESIN SYSTEMS
US20090087484A1 (en) * 2007-09-28 2009-04-02 Alza Corporation Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
AU2010223323B2 (en) 2009-03-10 2013-07-04 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
EP2554168B1 (en) 2010-03-29 2018-01-24 Astellas Pharma Inc. Controlled release pharmaceutical composition
MX367010B (es) 2010-12-22 2019-08-02 Purdue Pharma Lp Formas de dosis de liberacion controlada encerradas resistentes a manipulaciones indebidas.
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
JP6236447B2 (ja) 2012-07-16 2017-11-22 ローズ テクノロジーズ 改善されたオピオイド合成方法
KR101946104B1 (ko) 2012-07-16 2019-02-08 로드스 테크놀로지즈 개선된 오피오이드 합성을 위한 방법
KR20250154562A (ko) 2012-11-02 2025-10-28 머레이 앤 풀 엔터프라이지즈, 리미티드 콜히친 유도체의 투여를 통한 심혈관성 병태의 치료 또는 예방
CN105120846B (zh) 2013-02-05 2019-10-18 普渡制药公司 抗篡改的药物制剂
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
AU2014255434B2 (en) 2013-04-16 2018-11-08 Murray And Poole Enterprises Limited Sustained-release formulations of colchicine and methods of using same
EP2991680A1 (en) 2013-04-30 2016-03-09 AbbVie Inc. Methods for improving lipid profiles using atrasentan
EP3024461B1 (en) 2013-07-23 2020-05-13 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9932348B2 (en) 2014-01-15 2018-04-03 Rhodes Technologies Process for improved oxycodone synthesis
ES2672795T3 (es) 2014-01-15 2018-06-18 Rhodes Technologies Proceso para la síntesis mejorada de oximorfona
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
WO2016166732A1 (en) 2015-04-17 2016-10-20 Murray And Poole Enterprises Limited Colchicine salicylate and uses thereof
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US11534415B2 (en) 2018-02-02 2022-12-27 Murray And Poole Enterprises Ltd Use of colchicine to inhibit tumor growth and metastases
WO2021029020A1 (ja) 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
WO2021089715A1 (en) 2019-11-06 2021-05-14 Murray And Poole Enterprises, Ltd. Use of colchicine in the treatment and prevention of lung cancer
WO2021252741A1 (en) 2020-06-10 2021-12-16 Auspex Pharmaceuticals, Inc. Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
KR20250019144A (ko) 2022-06-08 2025-02-07 오스펙스 파마슈티칼스, 인코포레이티드 듀테트라베나진을 포함하는 삼투성 제형 및 이의 사용 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3211645A (en) * 1962-07-17 1965-10-12 Technicon Instr Method and apparatus for filtering sanguineous liquid streams
US3305097A (en) * 1963-05-27 1967-02-21 Scientific Industries High pressure peristaltic pump for separation apparatus

Also Published As

Publication number Publication date
ZA70548B (en) 1971-08-25
NL7001662A (Direct) 1970-08-07
FR2033961A5 (Direct) 1970-12-04
GB1307331A (en) 1973-02-21
US3541005A (en) 1970-11-17
BE745442A (fr) 1970-07-16
DE2005260A1 (de) 1970-10-29
DK141682C (Direct) 1980-10-20
JPS4931431B1 (Direct) 1974-08-21
SE350702B (Direct) 1972-11-06

Similar Documents

Publication Publication Date Title
DK141682B (da) Fremgangsmåde til ultrafiltrering af opløsninger, der indeholder geldannende dispergerede partikler eller geldannende makromolekyler.
Drioli et al. Membrane distillataion in the treatment of aqueous solutions
Riley et al. Preparation of ultrathin reverse osmosis membranes and the attainment of theoretical salt rejection
Strathmann Membrane separation processes
US5098575A (en) Method and apparatus for processing liquid solutions of suspensions particularly useful in the desalination of saline water
Wang et al. The characterization of flat composite nanofiltration membranes and their applications in the separation of Cephalexin
Nabetani et al. Effects of osmotic pressure and adsorption on ultrafiltration of ovalbumin
US4781837A (en) Method of performing osmetic distillation
US3133137A (en) High flow porous membranes for separating water from saline solutions
US3133132A (en) High flow porous membranes for separating water from saline solutions
Almazán et al. Nanofiltration of glucose: Analysis of parameters and membrane characterization
Al-Anezi et al. Potential of membrane distillation–a comprehensive review
IL34860A (en) Shaped articles such as films,membranes,porous supports,hollow fibers and the like,based on polypiperazineamides,tobbe used in reverse osmosis processes
CHERYAN Mass transfer characteristics of hollow fiber ultrafiltration of soy protein systems
Gupta et al. Characterization of nanofiltration and reverse osmosis membrane performance for aqueous salt solutions using irreversible thermodynamics
US3250701A (en) Stabilization of desalination membranes
El Mokhtar et al. Modeling and experimental study of air gap membrane distillation unit: application for seawater desalination
Fernandez et al. Cross flow filtration of RNA extracts by hollow fiber membrane
JPS6362504A (ja) 有機成分含有水溶液中の有機成分の濃縮方法
Tomaszewska Membrane distillation
Belhocine et al. Optimization of plasma proteins concentration by ultrafiltration
Gabino et al. Evaluation of the cleaning of a new hydrophobic membrane for osmotic evaporation
US3544455A (en) Itaconic acid purification process using reverse osmosis
US3520960A (en) Method of making microphorous cellulose nitrate films
Shalini et al. Forward osmosis membrane concentration of raw sugarcane juice